Ms. Fisher is a senior life sciences executive with over 15 years of experience spanning business development, corporate strategy, investor relations, and deal structuring across biotech, pharma, and medtech. She has a proven track record of closing complex licensing transactions, raising capital, and building global partnerships.
Ms. Fisher is currently Chief Business Officer at BioGenCell, a biotechnology company developing an autologous cell therapy for no-option Critical Limb-Threatening Ischemia, where she leads BioGenCell’s capital raising strategy to support a Phase 3 trial as well as commercial planning. From 2020 to 2025, Ms. Fisher was Head of Corporate Development at LifeSci Partners, an integrated life sciences advisory firm, where she supported business development and growth of the entire LifeSci Partners platform including LifeSci Advisors, LifeSci Capital, LifeSci Ventures, LifeSci Consulting, and LifeSci Search.
Earlier in her career she was Head of Business Development & Licensing at Neopharm, a multinational pharmaceutical company, Head of Strategic Alliances and Corporate Development at SK Pharma. Ms. Fisher holds a B.Sc. degree in Biotechnology and M.A. in Law from Bar-Ilan University bringing deep scientific fluency along with financial acumen.
What is Michal Fisher's net worth?
The estimated net worth of Michal Fisher is at least $10.85 thousand as of May 18th, 2026. Ms. Fisher owns 2,000 shares of CNS Pharmaceuticals stock worth more than $10,850 as of October 7th. This net worth approximation does not reflect any other assets that Ms. Fisher may own. Learn More about Michal Fisher's net worth.
How do I contact Michal Fisher?
Has Michal Fisher been buying or selling shares of CNS Pharmaceuticals?
Michal Fisher has not been actively trading shares of CNS Pharmaceuticals over the course of the past ninety days. Most recently, on Monday, May 18th, Michal Fisher bought 2,000 shares of CNS Pharmaceuticals stock. The stock was acquired at an average cost of $5.00 per share, with a total value of $10,000.00. Following the completion of the transaction, the director now directly owns 2,000 shares of the company's stock, valued at $10,000. Learn More on Michal Fisher's trading history.
Who are CNS Pharmaceuticals' active insiders?
Are insiders buying or selling shares of CNS Pharmaceuticals?
During the last year, CNS Pharmaceuticals insiders bought shares 2 times. They purchased a total of 9,100 shares worth more than $44,009.00. The most recent insider tranaction occured on May, 18th when Director Faith L Charles bought 7,100 shares worth more than $34,009.00. Insiders at CNS Pharmaceuticals own 1.8% of the company.
Learn More about insider trades at CNS Pharmaceuticals. Information on this page was last updated on 5/18/2026.
